Partner With a Dedicated Phase II/III CRO

"The depth of experience in the indication (hypertension) [and] the team they proposed -- the medical monitor, the project manager, and the clinical study lead -- were all very, very strong in [the] indication and the dynamics of the team […] and then again with us was very strong.”

"They (Worldwide Clinical Trials) are focused on design and appropriate execution and reporting of clinical trial data. Everything else that’s necessary for that is all there to drive the success and the execution in reporting of acceptable clinical trial data. (...) The mission is pretty clear. And you know, and I do think the flexibility comes across. Because when you deal with big CROs, if we make a change in a process because we think that’s the right thing to do, it’s not enough for them just to do it because we want it. (...) They’re less concerned about that at Worldwide, in my experience. They’re more concerned about doing the right thing.”

“One of the things that was very impressive and powerful in their presentation to the organization when Worldwide came to do the bid defense were the metrics they had for patient recruitment, investigator engagement, and all those kinds of things. (...) and the demonstration they gave of how their system works to produce these metrics and to make a risk assessment of what the challenges are to do the study -- they did a really good job with that.”

“From our point of view, what was really differentiating [Worldwide] was a detailed action plan when it came to site selection with respect to their local country, local regulatory knowledge. It was them demonstrating from similar studies showing how they had run those similar studies in a very competitive time [and with] very persuasive patient recruitment metrics. It was about how quickly they could start up comparable clinical trials, and their proposed use of real-world data to better optimize the clinical – operation and execution of the clinical trial, again where to find patients, in which country preferably, and which sites.”